Are the Current Recommendations for Chloroquine and Hydroxychloroquine Screening Appropriate? Review uri icon

Overview

abstract

  • Hydroxychloroquine and quinacrine are frequently used to treat rheumatic diseases. Ocular toxicity, although infrequent, is one of the potential side effects of antimalarial therapies. Current recommendations are unifocal in being developed by only ophthalmologists who do not treat patients for their rheumatic diseases. The data used to create the recommendations are meager and retrospective. Comanagement of patients with rheumatic disease who are exposed to antimalarial therapies requires a greater interaction between ophthalmologists and rheumatologists.

publication date

  • May 30, 2019

Research

keywords

  • Chloroquine
  • Eye Diseases
  • Hydroxychloroquine
  • Rheumatic Diseases

Identity

Scopus Document Identifier

  • 85066240051

Digital Object Identifier (DOI)

  • 10.1016/j.rdc.2019.04.008

PubMed ID

  • 31277749

Additional Document Info

volume

  • 45

issue

  • 3